ExchangePrior AuthLow impact
Drug Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Infectious Disease, Oncology, Hematology·Pharmacy
Effective date
Mar 18, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated the indication criteria for Noxafil (posaconazole) to match the drug's updated FDA labeling. This affects prior authorization requirements and coverage determinations for this antifungal medication across Exchange, Standard, Complete, and Essential plan types.
Action Required
By March 18, 2026: Billing team should review updated indication criteria for Noxafil (posaconazole) prior authorization requests. Update any internal formulary references and ensure providers are aware of revised indication questions when submitting prior auth requests for Arkansas Blue Cross Exchange, Standard, Complete, and Essential plans.